[Ultraviolet-A1 (UVA1) phototherapy in lichen sclerosus et atrophicus].
Two patients, a nine year old girl and a 59 year old woman, presented with extensive and recalcitrant lichen sclerosus et atrophicus (LSA). Both patients were treated with low-dose ultraviolet-A1 (UVA1) phototherapy (340-400 nm) for ten weeks. The cumulative UVA1 dose was 800 J/cm(2), the single UVA1 dose was 20 J/cm(2). After 40 treatment sessions, the previously sclerotic skin lesions had almost completely cleared in both patients. In addition 20-MHz ultrasound examination and histological specimen revealed no further signs of sclerosis. UVA1 phototherapy seems to be a new and effective treatment for LSA with optimal patients' acceptance due to the absence of systemic side effects. UVA1 should be therefore considered as therapeutic option for LSA.
Kreuter
A
A
Dermatologische Klinik der Ruhr-Universität Bochum.
von Kobyletzki
G
G
Happe
M
M
Herde
M
M
Breuckmann
F
F
Stücker
M
M
Altmeyer
P
P
D002648:Child; D005260:Female; D006801:Humans; D018459:Lichen Sclerosus et Atrophicus / Q000473:pathology* / Q000532:radiotherapy*; D008875:Middle Aged; D011829:Radiation Dosage; D016896:Treatment Outcome; D014467:Ultraviolet Therapy / Q000379:methods*